Last updated: August 1, 2026
Brompheniramine maleate plus pseudoephedrine hydrochloride is a mature oral antihistamine-decongestant combination used for temporary relief of runny nose, sneezing, nasal congestion and related upper-respiratory symptoms. The combination has no meaningful branded-innovator exclusivity remaining, no active late-stage clinical development program identified in public trial databases, and a fragmented generic market. Commercial performance is driven by seasonal demand, retailer distribution, state-level pseudoephedrine controls and product availability rather than clinical differentiation.
The main growth opportunity is in low-cost private-label and generic liquid products. The main risks are substitution by newer nonsedating antihistamines, combination products containing dextromethorphan or acetaminophen, tighter pseudoephedrine controls and limited pricing power.
What is brompheniramine maleate and pseudoephedrine hydrochloride used for?
Brompheniramine is a first-generation H1 antihistamine. Pseudoephedrine is an oral sympathomimetic nasal decongestant. Together, they address multiple cold and allergy symptoms:
| Component |
Pharmacologic role |
Common adverse effects |
| Brompheniramine maleate |
Reduces histamine-mediated sneezing, rhinorrhea and itching |
Sedation, dry mouth, blurred vision, urinary retention |
| Pseudoephedrine hydrochloride |
Reduces nasal congestion through vasoconstriction |
Insomnia, nervousness, palpitations, increased blood pressure |
A widely marketed oral liquid contains brompheniramine maleate 2 mg and pseudoephedrine hydrochloride 30 mg per 5 mL. Some products combine the same ingredients with dextromethorphan. Those products should be analyzed separately because their labeling, competitive set and formulation claims differ.
Brompheniramine-pseudoephedrine products are used for symptoms associated with the common cold, allergic rhinitis and upper-respiratory congestion. They do not treat the underlying viral infection and are not antibacterial or antiviral therapies.
What is the FDA regulatory status of brompheniramine-pseudoephedrine?
The combination is an established FDA-regulated over-the-counter and prescription-market product, depending on the specific formulation and labeling. The active ingredients are covered by the FDA’s OTC monograph framework for antihistamines and nasal decongestants, subject to applicable conditions for safety, dosage and labeling under 21 C.F.R. Part 341.
The regulatory position has three practical consequences:
- New products generally do not need a novel clinical efficacy program if they comply with the applicable OTC monograph conditions.
- Products that differ materially from the monograph may require an FDA drug application or another regulatory pathway.
- A product can remain prescription-only because of formulation, labeling or commercial strategy even when its active ingredients have long OTC histories.
Pseudoephedrine is also subject to federal sales restrictions under the Combat Methamphetamine Epidemic Act. Retailers must record purchases, enforce daily and monthly quantity limits and maintain required security controls. State laws can impose additional requirements.
What is the Orange Book status of brompheniramine-pseudoephedrine?
The combination does not have a current, commercially meaningful reference-product exclusivity position comparable to a patented prescription drug. Legacy products and prescription formulations may appear in FDA product and therapeutic-equivalence records, but the market is primarily supplied through generic, private-label and OTC channels.
Orange Book relevance depends on the specific product, strength, dosage form and application number. An Orange Book listing does not itself create exclusivity. Generic applicants face patent certification obligations only where applicable listed patents exist for the referenced product.
What clinical trials have evaluated brompheniramine and pseudoephedrine?
Public clinical-trial records do not identify an active late-stage development program focused on brompheniramine maleate plus pseudoephedrine hydrochloride as a new therapeutic combination. The evidence base is primarily historical pharmacology, controlled symptom studies, post-market safety data and regulatory reviews rather than modern sponsor-led Phase 2 or Phase 3 development.
Clinical evidence has generally supported short-term symptomatic relief from antihistamine-decongestant combinations. The limitations are well established:
- First-generation antihistamines can impair alertness and psychomotor performance.
- Oral pseudoephedrine can cause insomnia, cardiovascular stimulation and blood-pressure increases.
- Combination products make it harder to isolate the contribution of each ingredient.
- Pediatric use requires strict attention to age, dose and duplicate-ingredient exposure.
- Evidence for routine use in very young children is limited, and FDA labeling restricts use in children under two years without medical direction.
The current clinical-development profile is therefore maintenance-oriented. Companies compete through formulation, packaging, distribution and compliance rather than by generating new efficacy data.
Are there biosimilar or biologic risks?
No. Brompheniramine maleate and pseudoephedrine hydrochloride are small-molecule active ingredients. Biosimilar regulation is irrelevant. Competitive entry occurs through generic drug applications, OTC monograph products, private-label products and, in some cases, authorized-generic arrangements.
What patents protect brompheniramine maleate and pseudoephedrine hydrochloride?
No commercially significant unexpired composition-of-matter patent estate protects the active ingredients. Brompheniramine and pseudoephedrine have been used in medicinal products for decades, and basic active-ingredient protection has expired.
The relevant IP categories are narrower:
| IP category |
Current commercial relevance |
| Composition-of-matter patents |
Essentially exhausted |
| Basic combination patents |
Historical protection has expired |
| Extended-release technology |
Potentially relevant for a specific dosage form, but not for the standard immediate-release combination |
| Liquid formulation patents |
Possible for excipient systems, taste masking or stability, but generally narrow |
| Manufacturing patents |
May protect a process, although alternative manufacturing routes are available |
| Trademark and trade dress |
More commercially relevant than active-ingredient patents |
| Method-of-use patents |
Limited practical value for ordinary cold and allergy symptom relief |
A formulation patent could create a barrier for a particular product if it claimed a novel release profile, preservative system, taste-masking platform or stability profile. It would not prevent competing products using the same active ingredients in conventional formulations.
How strong is the patent estate?
The patent estate is weak for the core combination and potentially moderate for a differentiated dosage form. Patent risk is low for standard immediate-release tablets and syrups. Risk increases when a product relies on:
- A proprietary extended-release profile
- A specialized pediatric liquid vehicle
- A protected preservative or flavor system
- A branded delivery device
- A drug-device combination
- A product-specific formulation patent listed for a reference product
The absence of strong active-ingredient patents shifts competitive risk toward regulatory exclusivity, supply reliability, trademarks and distribution contracts.
When does brompheniramine-pseudoephedrine lose exclusivity?
Core exclusivity has already expired. There is no meaningful remaining new-drug exclusivity period for the established active ingredients.
| Exclusivity type |
Status |
| New chemical entity exclusivity |
Expired or not applicable |
| Basic composition patent |
Expired |
| Combination patent |
Historical protection expired |
| Pediatric exclusivity |
No current commercial significance |
| Orphan-drug exclusivity |
Not applicable |
| Biosimilar exclusivity |
Not applicable |
| Formulation exclusivity |
Product-specific and potentially relevant only where a protected formulation exists |
Generic or private-label entry does not depend on a single future loss-of-exclusivity event. Entry is already established.
Which companies compete in this market?
Competition is fragmented across branded OTC manufacturers, generic pharmaceutical companies, contract manufacturers and retailers.
Relevant market participants may include:
- Perrigo
- Haleon
- Kenvue
- Prestige Consumer Healthcare
- Bausch Health and legacy prescription-generic businesses
- Major generic manufacturers
- Regional liquid-dose manufacturers
- Retail private-label programs operated by pharmacy, grocery and mass-merchandise chains
The exact supplier list varies by dosage form and channel. A bottle sold under a retailer brand may be manufactured by a third party and may change suppliers without a visible consumer-brand change.
The market has several competitive segments:
| Segment |
Representative competitive logic |
| Brompheniramine-pseudoephedrine only |
Low-cost symptom coverage |
| Brompheniramine-pseudoephedrine-dextromethorphan |
Adds cough suppression |
| Acetaminophen-containing cold products |
Adds pain and fever relief |
| Newer antihistamines |
Lower sedation and longer duration |
| Phenylephrine products |
Alternative decongestant, although oral efficacy has faced FDA scrutiny |
| Intranasal decongestants |
Faster local relief, with duration-of-use limits |
| Saline and non-drug products |
Lower safety burden and growing consumer acceptance |
What is the market size and revenue outlook?
Public companies generally do not report revenue specifically for brompheniramine maleate plus pseudoephedrine hydrochloride. Reported figures usually aggregate the product into broader OTC cough, cold, allergy or respiratory portfolios.
The market is mature and low growth in volume. Revenue is affected by:
- Winter respiratory-virus intensity
- Allergy seasons
- Retail inventory levels
- Product recalls and manufacturing interruptions
- Pseudoephedrine purchase restrictions
- Consumer migration to nonsedating antihistamines
- Private-label penetration
- Price inflation and retailer negotiations
A realistic base-case projection is for low-single-digit annual value growth over a five-year period, with unit demand broadly flat or modestly declining. Price and mix can produce positive dollar growth even when volumes fall.
Five-year scenario projection
The following scenario is an analytical market projection for products containing the two active ingredients, not a reported industry forecast.
| Scenario |
Volume trend |
Value trend |
Main assumptions |
| Downside |
-4% to -6% annually |
-3% to -5% annually |
Continued migration to newer antihistamines, tighter pseudoephedrine controls and retailer delisting |
| Base case |
-1% to +1% annually |
0% to +3% annually |
Stable seasonal demand, modest price increases and continued generic availability |
| Upside |
+1% to +3% annually |
+3% to +6% annually |
Strong respiratory seasons, improved supply and successful pediatric-liquid or private-label expansion |
The most attractive commercial opportunities are unlikely to come from premium pricing. They are more likely to come from reliable supply, retailer authorization, liquid formulation capacity, compliant pseudoephedrine distribution and bundled cold-symptom products.
What manufacturing and supply-chain barriers affect entry?
Manufacturing barriers are moderate rather than high. The active ingredients are established and available from multiple sources. Standard tablets and oral liquids do not require highly specialized production equipment.
The principal barriers are operational:
- Controlled handling and inventory reporting for pseudoephedrine products
- Federal and state retail compliance
- Stability and preservative validation for oral liquids
- Taste masking and pediatric acceptability
- Packaging designed to reduce dosing errors
- Seasonal demand forecasting
- FDA-compliant labeling and OTC monograph alignment
- Retailer qualification and vendor approval
- Avoidance of duplicate acetaminophen, antihistamine or decongestant exposure in combination products
Supply disruption can have a larger commercial effect than patent litigation. A manufacturer with reliable API procurement, validated liquid capacity and retailer relationships can gain share even without proprietary IP.
What generic launch risks exist?
Generic launch risk is low for conventional immediate-release products but higher for differentiated formulations.
Low-risk launch profile
A low-risk entrant would use:
- Established strengths
- Conventional immediate-release tablets or oral liquid
- Monograph-compatible labeling
- Standard excipients
- No reliance on a protected delivery device
- Multiple API suppliers
- Retail or wholesale distribution already established
Higher-risk launch profile
Risk increases where the product requires:
- A novel extended-release profile
- A pediatric formulation with unusual excipients
- A formulation patent challenge
- A prescription-to-OTC switch
- State-specific pseudoephedrine distribution systems
- A single-source API or contract manufacturer
- A product-specific patent certification
Commercial launch timing is more likely to be constrained by FDA review, manufacturing readiness or retailer placement than by a basic patent barrier.
What litigation and settlements affect the combination?
There is no widely recognized current patent-litigation campaign centered on the basic brompheniramine-pseudoephedrine combination. Litigation exposure is more likely to arise from:
- Product liability claims involving sedation, cardiovascular effects or pediatric dosing
- Labeling and advertising disputes
- False or misleading OTC claims
- Trademark and trade-dress disputes
- Contract-manufacturing disagreements
- State enforcement involving pseudoephedrine sales controls
- Patent disputes involving a specific extended-release or liquid formulation
No industry-defining settlement agreement appears to control generic entry for the ordinary immediate-release combination. Any diligence should review the exact National Drug Code, application number, dosage form and manufacturer because litigation and patent relevance can attach to a product-specific formulation rather than to the active ingredients generally.
How does brompheniramine-pseudoephedrine compare with competing products?
| Product category |
Sedation |
Decongestant effect |
Patent strength |
Market position |
| Brompheniramine-pseudoephedrine |
Moderate to high |
Established oral option |
Low |
Generic and private-label |
| Loratadine-pseudoephedrine |
Lower antihistamine sedation |
Established |
Low to moderate, product-specific |
Strong allergy-decongestant segment |
| Cetirizine-pseudoephedrine |
Lower than first-generation antihistamines for many users |
Established |
Low |
Competes in allergy-focused products |
| Dextromethorphan-containing combinations |
Depends on antihistamine |
Established |
Low |
Stronger cold-symptom positioning |
| Acetaminophen-containing combinations |
Depends on antihistamine |
Established |
Low |
Broad symptom coverage |
| Intranasal corticosteroids |
Minimal systemic sedation |
Not a direct oral decongestant substitute |
Product-specific |
Strong allergic-rhinitis competitor |
Brompheniramine-pseudoephedrine retains value where consumers prioritize broad symptom relief and low price. It is less competitive where nonsedating treatment, once-daily dosing or long-term allergy control is the primary need.
What is the geographic coverage of the market?
The United States is the most commercially relevant market because pseudoephedrine regulation, OTC monograph rules and retail distribution materially shape demand. Other jurisdictions may classify pseudoephedrine more restrictively, require prescription access or use different antihistamine combinations.
Geographic expansion is therefore regulatory rather than patent-led. A company entering multiple markets must address:
- Country-specific scheduling of pseudoephedrine
- Local OTC or prescription status
- Maximum daily dose limits
- Pediatric labeling
- Combination-product authorization
- Import controls
- Pharmacovigilance requirements
- Local language and packaging rules
The absence of U.S. patent barriers does not guarantee rapid international entry.
Key Takeaways
- Brompheniramine maleate plus pseudoephedrine hydrochloride is a mature, established antihistamine-decongestant combination.
- No active late-stage clinical development program is associated with the basic combination in public trial records.
- Core composition and combination patent protection has expired.
- Biosimilar risk is irrelevant because both ingredients are small molecules.
- The FDA pathway is primarily OTC monograph compliance, although specific products may remain prescription products.
- Pseudoephedrine controls are the principal regulatory and operational constraint.
- The market is fragmented, price-sensitive and seasonal.
- Base-case value growth is likely to remain in the 0% to 3% annual range, with unit demand flat to modestly declining.
- Formulation, liquid-dose manufacturing, retailer access and supply reliability are more important than basic active-ingredient IP.
- Litigation risk is product-specific and more likely to involve labeling, liability, trademarks or differentiated formulations than core patent protection.
FAQs about brompheniramine maleate and pseudoephedrine hydrochloride
Is brompheniramine-pseudoephedrine still commercially attractive?
Yes, but mainly as a volume and distribution business. The combination has limited pricing power and little composition-of-matter protection. Commercial value depends on retailer access, reliable supply and private-label contracts.
Can a company obtain a new patent on brompheniramine and pseudoephedrine?
A basic combination patent is unlikely to provide meaningful protection. A company may pursue narrower patents covering extended release, taste masking, stability, excipients, packaging or a drug-device system.
Are brompheniramine-pseudoephedrine products eligible for generic substitution?
Eligibility depends on the specific product, dosage form, strength and regulatory application. Conventional products may be therapeutically substitutable where an FDA-approved generic has the relevant rating. OTC private-label products may follow a different monograph-based pathway.
Does pseudoephedrine’s methamphetamine-control status prevent online sales?
It restricts how pseudoephedrine can be sold. Federal requirements include purchaser identification, transaction records, quantity limits and secure storage. Online and mail-order sales may require additional compliance controls and can be restricted by state law.
Is brompheniramine-pseudoephedrine safer than newer allergy medicines?
It has a longer history of use but generally has greater sedation and anticholinergic burden than newer nonsedating antihistamines. Pseudoephedrine also creates cardiovascular and sleep-related concerns that do not apply to antihistamine-only products.
References
-
U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. Electronic Code of Federal Regulations.
-
U.S. Food and Drug Administration. (2024). Drug database and Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov
-
U.S. Food and Drug Administration. (2024). ClinicalTrials.gov search records for brompheniramine and pseudoephedrine hydrochloride. https://clinicaltrials.gov
-
U.S. Congress. (2005). Combat Methamphetamine Epidemic Act of 2005, Title VII of the USA PATRIOT Improvement and Reauthorization Act.
-
U.S. Food and Drug Administration. (2024). Drug products containing pseudoephedrine: Retail sales and regulatory requirements. https://www.fda.gov
-
U.S. Food and Drug Administration. (2008). Use caution when giving cough and cold products to kids. https://www.fda.gov
-
U.S. Food and Drug Administration. (2023). FDA briefing materials on oral phenylephrine effectiveness. https://www.fda.gov
